FR226807: a potent and selective phosphodiesterase type 5 inhibitor

By Hosogai N.   Hamada K.   Tomita M.   Nagashima A.   Takahashi T.   Sekizawa T.   Mizutani T.   Urano Y.   Kuroda A.   Sawada K.   Ozaki T.   Seki J.   Goto T.  

European Journal of Pharmacology, Vol. 428, Iss. 2, 2001-10 ,pp. : 295-302

Elsevier

Access to resources Recommend Favorite

Enzymological and pharmacological profile of T-0156, a potent and selective phosphodiesterase type 5 inhibitor

By Mochida H.   Takagi M.   Inoue H.   Noto T.   Yano K.   Fujishige K.   Sasaki T.   Yuasa K.   Kotera J.   Omori K.   Kikkawa K.  

European Journal of Pharmacology, Vol. 456, Iss. 1, 2002-12 ,pp. : 91-98

Elsevier

Access to resources Recommend Favorite

Cardiovascular activity of WIN 65579, a novel inhibitor of cyclic GMP phosphodiesterase 5

By Silver P.J.   Pagani E.D.   Dundore R.L.   de Garavilla L.   Bode D.C.   Bacon E.R.  

European Journal of Pharmacology, Vol. 349, Iss. 2, 1998-05 ,pp. : 263-268

Elsevier

Access to resources Recommend Favorite

Rolipram, a cyclic AMP-selective phosphodiesterase inhibitor, reduces neuronal damage following cerebral ischemia in the gerbil

By Kato H.   Araki T.   Itoyama Y.   Kogure K.  

European Journal of Pharmacology, Vol. 272, Iss. 1, 1995-01 ,pp. : 107-110

Elsevier

Access to resources Recommend Favorite

Avanafil, a new rapid-onset phosphodiesterase 5 inhibitor for the treatment of erectile dysfunction

By Limin Ma   Johnsen Niels   Hellstrom Wayne JG  

Expert Opinion on Investigational Drugs, Vol. 19, Iss. 11, 2010-11 ,pp. : 1427-1437

Informa Healthcare

Access to resources Recommend Favorite